Pins matching tag:Wegovy

On 29 July 2025 Novo Nordisk appointed Maziar Mike Doustdar, head of International Operations, as president and CEO from 7 August 2025, succeeding Lars Fruergaard Jørgensen after 34 years with the company.

On 22 December 2025 the US FDA approved the once-daily Wegovy pill (oral semaglutide 25 mg), the first oral GLP-1 for weight management, which showed 16.6% mean weight loss in the OASIS 4 trial.

On 3 February 2026 Novo Nordisk reported 2025 sales up 10% at constant exchange rates to DKK 309.1 billion but guided 2026 adjusted sales and operating profit down 5-13%, citing lower US prices and competition.

On 19 March 2026 the US FDA approved Wegovy HD (semaglutide 7.2 mg, once weekly) for weight loss after the STEP UP trial showed 20.7% mean weight loss, the first GLP-1 approval under the FDA's priority voucher pilot.

On 4 August 2026 Novo Nordisk reported Q2 adjusted sales up 7% and adjusted operating profit up 11% at constant exchange rates and raised its 2026 outlook to 0% to -6%, helped by stronger GLP-1 sales.